On March 9, 2026, the correction of errors to the Commission Implementing Regulation (EU) 2019/1262, relating to the authorization of medicinal products for human use, was published. Although at first glance this may seem like a minor formality, this type of correction—technically known as errata—has real implications for companies in the pharmaceutical sector that must ensure compliance with the current and updated regulatory text at all times. If your company manufactures, distributes or markets medicines in the European Union, this article explains what you need to know.
What does this regulation establish?
This document is an official correction of errors to Implementing Regulation (EU) 2019/1262, issued by the European Commission. Corrections of this type are intended to remedy technical or editorial aspects detected in the original text, without modifying the substantive scope of the regulation.
It is important to understand what this means in practice:
- The essential content of the original Regulation does not change.
- Errors in form, wording or specific technical aspects of the text are corrected.
- The corrected text becomes the official and valid text for all legal purposes.
- Any internal reference to the regulation must be made to the updated consolidated text.
Since the date of entry into force has not been expressly specified in the publication, it is recommended to consult the original regulation to learn the specific details about its temporal application.
Who does it affect and how?
This correction primarily affects agents in the pharmaceutical sector operating within the European Union. Specifically, those most impacted are:
- Pharmaceutical companies that have obtained or are processing marketing authorizations for human medicines.
- Pharmaceutical laboratories that develop, manufacture or analyze medicines subject to Regulation 2019/1262.
- Medicine distributors in the EU that base their operational procedures on the text of this regulation.
For the majority of business sectors outside the pharmaceutical field, the practical impact of this correction is limited or non-existent. However, for the actors in the sector mentioned, ignoring an official errata could mean working with outdated internal documentation, which could generate problems in audits, inspections or administrative proceedings before the competent authorities.
A practical example: if a laboratory has its standard operating procedures (SOPs) referencing the previous text of the Regulation, it must verify whether the corrections introduced affect any of those procedures and update them accordingly.
What should you do to adapt?
Although the substantive impact of this correction is limited, regulatory diligence requires taking certain measures. We recommend the following steps:
- Consult the updated consolidated text of Implementing Regulation (EU) 2019/1262 on EUR-Lex to identify exactly what aspects have been corrected.
- Review your company's internal documentation: procedures, protocols, contracts or any document that makes direct reference to the text of the original Regulation.
- Update regulatory references in internal documents that require it, replacing any citation to the previous text with the corrected version.
- Inform compliance teams (compliance, regulatory affairs, quality) about the publication of this correction so they can assess its impact on current procedures.
- Consult a professional specialized in pharmaceutical regulation if there are doubts about how this correction affects ongoing authorizations or active administrative procedures.
Remember that in the European pharmaceutical regulatory field, working with outdated regulatory texts can have consequences in authorization, renewal or inspection processes. Due diligence in monitoring errata and corrections is part of good regulatory compliance management.
For any specific details on deadlines, sanctions or specific consequences arising from this correction, we recommend consulting the original regulation directly from the official source.
Official source
Consult complete regulation at official source
Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions regarding your situation, consult a qualified professional. Original source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=CELEX:32019R1262R(01)
📋 Consult the full details of this regulation on CambiosLegales